Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brequinar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH known ✓ | Q02127 | 19/20 | 1.00 |
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brequinar SCHEMBL29688590 | 1.00 | DHODH (1.00) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL49400 | 1.00 | DHODH (1.00) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL23832490 | 1.00 | DHODH (1.00) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL11906320 | 0.99 | DHODH (0.98) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL23113785 | 0.99 | DHODH (0.98) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL21378179 | 0.99 | DHODH (0.98) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL23828306 | 0.99 | DHODH (0.98) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL4266 | 0.99 | DHODH (0.98) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL27742234 | 0.97 | DHODH (0.94) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL4177875 | 0.96 | DHODH (0.92) | DHODHDHFRALKBH5PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281362-B2 | Diagnostic tools and treatments for clear cell renal cell carcinoma | UNIVERSITY OF CINCINNATI (US) | 2025-04-22 | — | — | US | claimed |
| US-20230136218-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-05-04 | — | — | US | claimed |
| US-20220136059-A1 | Diagnostic Tools and Treatments for Clear Cell Renal Cell Carcinoma | UNIVERSITY OF CINCINNATI (US) | 2022-05-05 | — | — | US | claimed |
| US-12594271-B2 | Combination therapy for cancer | HEALTH RESEARCH, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4649086-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4626439-A2 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA | The Regents of the University of Colorado, a body corporate (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4622959-A1 | 2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250248989-A1 | STABLE POLYMORPHIC COMPOSITIONS OF BREQUINAR SODIUM AND METHODS OF USE AND MANUFACTURE THEREOF | CLEAR CREEK BIO INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250223259-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2025-07-10 | — | — | US | disclosed |
| US-12281362-B2 | Diagnostic tools and treatments for clear cell renal cell carcinoma | UNIVERSITY OF CINCINNATI (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025041128-A1 | BRAIN PERMEABLE DHODH INHIBITORS AND USES THEREOF | SELENE THERAPEUTICS LTD. (IL) | 2025-02-27 | — | — | WO | disclosed |
| EP-4054628-A1 | COMBINATION THERAPY FOR CANCER | Health Research, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022171682-A1 | THERAPEUTIC COMPOSITION BASED ON DHODH- INHIBITING NEUROLAENA LEAVES FOR THE TREATMENT OF RNA VIRUS INFECTIONS | PHYTOBOKAZ (FR) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022173711-A1 | METHOD OF TREATING CANCER WITH NUCLEOTIDE THERAPEUTICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20220249534-A1 | METHOD OF TREATING CANCER WITH NUCLEOTIDE THERAPEUTICS | THE GENERAL HOSPITAL CORPORATION | 2022-08-11 | — | — | US | disclosed |
| US-20220177435-A1 | COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE | Clear Creek Bio, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220136059-A1 | Diagnostic Tools and Treatments for Clear Cell Renal Cell Carcinoma | UNIVERSITY OF CINCINNATI (US) | 2022-05-05 | — | — | US | disclosed |
| US-11312686-B2 | Methods and compositions for inhibition of dihydroorotate dehydrogenase | OHIO STATE INNOVATION FOUNDATION (US) | 2022-04-26 | — | — | US | disclosed |
| CN-114288294-A | Compounds and methods for treating or preventing hematologic cancers | 布罗德研究所股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11230528-B2 | Compositions and methods for inhibiting dihydroorotate dehydrogenase | Clear Creek Bio, Inc. | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230528-B2 | Compositions and methods for inhibiting dihydroorotate dehydrogenase | DHODH, DLD, DPYD | DHODH 1/4885DHFR 20/4885ALKBH5 608/4885 |
| US-11312686-B2 | Methods and compositions for inhibition of dihydroorotate dehydrogenase | DHODH, DLD, DPYD | DHODH 1/4885DHFR 5/4885ALKBH5 668/4885 |
| US-20250248989-A1 | STABLE POLYMORPHIC COMPOSITIONS OF BREQUINAR SODIUM AND METHODS OF USE AND MANUFACTURE THEREOF | HLA-DRB1, UBE2V1, BRCA1 | DHODH 1282/4885DHFR 425/4885ALKBH5 699/4885 |
| US-20250223259-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | ACE2, PRSS2, PRSS1 | DHODH 3790/4885DHFR 2930/4885ALKBH5 1924/4885 |
| US-12594271-B2 | Combination therapy for cancer | CSF3R, PDCD1, CD274 | DHODH 3928/4885DHFR 3866/4885ALKBH5 3752/4885 |
| US-20220177435-A1 | COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE | DHODH, DLD, DPYD | DHODH 1/4885DHFR 20/4885ALKBH5 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.